Eylea® International English

Eylea® (aflibercept) is an anti-VEGF injection indicated for wet age-related macular degeneration (AMD), diabetic macular edema, and macular edema due to retinal vein occlusion. By inhibiting VEGF, Eylea® helps control abnormal blood vessel growth and fluid leakage under the retina, stabilizing or potentially improving vision.

Recognized for its efficacy and proven clinical outcomes, Eylea® is often selected to preserve visual acuity and slow disease progression. Many patients experience meaningful improvements in everyday visual tasks when the therapy is administered consistently.

Each intravitreal injection is administered under sterile conditions by an ophthalmologist. Frequency of treatment—often every four to eight weeks—depends on disease activity, making regular follow-up essential for long-term management.

Eylea® is commonly prescribed by retinal specialists and ophthalmologists treating advanced retinal pathologies in patients at risk of progressive vision loss.

Disclaimers:

– For intravitreal administration by licensed ophthalmologists only.

– Prescription required. Not for self-administration by patients.

– Use a sterile technique and monitor intraocular pressure following the manufacturer’s recommended intervals.

– This product should only be used according to local regulations and medical guidelines.